CTOs on the Move

Adaptive Biotechnologies

www.adaptivebiotech.com

 
Adaptive Biotechnologies is a pioneer and leader in immune-driven medicine that aims to improve people`s lives by learning from the wisdom of their adaptive immune systems. Adaptive`s proprietary immune profiling platform reveals and translates insights from our adaptive immune systems with unprecedented scale and precision. Working with drug developers, clinicians and academic researchers, we are applying these insights to develop products that will transform the way diseases -- such as cancer, autoimmune conditions, and infectious diseases -- are diagnosed and treated.
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million

Executives

Name Title Contact Details
David Arbo
Sr Director of Information Technology Profile
Josh Schmidt
Senior Director, Information Security Profile
Mark Adams
Chief Technical Officer Profile
Mark Adams
Chief Operating Officer Profile

Funding

Adaptive Biotechnologies raised $195M on 05/07/2015

Similar Companies

Urigen Pharmaceuticals

Urigen Pharmaceuticals is a Burlingame, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BioTheryX

BioTheryX is a clinical-stage biopharmaceutical company focused on restoring protein homeostasis through protein modulation, including protein degradation as well as multi-kinase inhibition, to develop treatments that extend and improve the quality-of-life of patients with life-threatening diseases.

1910 Genetics

We are a biotechnology company integrating AI, computation and biological automation to accelerate the design of small molecule and protein therapeutics. Our mission is to decrease the timeline and cost of drug development, while improving the success rate of bring innovative medicines to patients in need.

Neuron23

Neuron23™ Inc. is an early stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases.

Ligand

Ligand is a biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. Our business model creates value for stockholders by providing a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Our goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable, diversified and lower-risk business than a typical biotech company. Our business model is based on doing what we do best: drug discovery, early-stage drug development, product reformulation and partnering. We partner with other pharmaceutical companies to leverage what they do best (late-stage development, regulatory management and commercialization) to ultimately generate our revenue. Visit our technical products: omniab.com, captisol.com, vernalis.com and ltptechnology.com.